Preprint: Please note that this article has not completed peer review.
Research article

Targeting claudin-4 enhances chemosensitivity of triple negative breast cancer

Yi Luo, Shingo Kishi, Takamitsu Sasaki, Hitoshi Ohmori, Rina Fujiwara-Tani, Shiori Mori, Kei Goto, Yukiko Nishiguchi, Takuya Mori, Masuo Kondo, Hiroki Kuniyasu
DOI: 10.21203/rs.2.12416/v1

Abstract

Background

Triple negative breast cancer (TNBC) possesses highly aggressive phenotype, treatment with limited options, and a poor prognosis. In this study, we examined the therapeutic effect of anti-claudin (CLDN)-4 extracellular domain antibody, 4D3, on TNBC.

Methods

The expression of CLDN4 and CLDN1 in invasive ductal carcinoma (IDC) was examined in 78 IDCs (from 2004 to 2009 in a single center). CLDN expression and the effect of 4D3 on proliferation were examined in in human IDC cell lines MCF-7 (luminal subtype) and MDA-468 (TNBC).

Results

In IDC cases, CLDN1 had lower expression than CLDN4 and correlated with histological grade. In contrast, expression of CLDN4 correlated with histological grade, receptor subtype, and stage. CLDN4 expression in the two cells was at the same level. In both cells, paclitaxel (PTX)-induced growth suppression was enhanced by 4D3. Furthermore, 4D3 increased both intracellular PTX concentration (in both cells) and apoptosis. In the mouse model, 4D3 promoted the antitumor effect of PTX on subcutaneous tumors and reduced lung metastasis. The combination of PTX and 4D3 reduced M2 macrophages and mesenchymal stem cells in the tumor. 4D3 also reduced stemness of the tumors in association with increase in the intratumoral pH. Moreover, concurrent treatment of 4D3, PTX, or tamoxifen; or with PTX and tamoxifen in MDA-468 also showed the same level of antitumor activity and survival as MCF-7. Furthermore, in bone metastasis model, combination of PTX and bisphosphonate with 4D3 promoted tumor growth in both cells.

Conclusions

CLDN4 targeting of the antibody facilitated existing therapeutic effects.

Keywords
claudin, tight junction, breast cancer, antibody, chemotherapy

Figures

Background

Methods

Results

Discussion

Conclusion

Abbreviations

Declarations

References

Tables

Supplementary Files

Comments (0)

Comments can take the form of short reviews, notes or questions to the author. Comments will be posted immediately, but removed and moderated if flagged.

Learn more about our company.

Preprint: Please note that this article has not completed peer review.
Research article

Targeting claudin-4 enhances chemosensitivity of triple negative breast cancer

Yi Luo, Shingo Kishi, Takamitsu Sasaki, Hitoshi Ohmori, Rina Fujiwara-Tani, Shiori Mori, Kei Goto, Yukiko Nishiguchi, Takuya Mori, Masuo Kondo, Hiroki Kuniyasu

STATUS: In Review

Comments: 0
PDF Downloads: 0
HTML Views: 4

Integrity Check:

  • Article

  • Peer Review Timeline

  • Related Articles

  • Comments

Abstract

Background

Triple negative breast cancer (TNBC) possesses highly aggressive phenotype, treatment with limited options, and a poor prognosis. In this study, we examined the therapeutic effect of anti-claudin (CLDN)-4 extracellular domain antibody, 4D3, on TNBC.

Methods

The expression of CLDN4 and CLDN1 in invasive ductal carcinoma (IDC) was examined in 78 IDCs (from 2004 to 2009 in a single center). CLDN expression and the effect of 4D3 on proliferation were examined in in human IDC cell lines MCF-7 (luminal subtype) and MDA-468 (TNBC).

Results

In IDC cases, CLDN1 had lower expression than CLDN4 and correlated with histological grade. In contrast, expression of CLDN4 correlated with histological grade, receptor subtype, and stage. CLDN4 expression in the two cells was at the same level. In both cells, paclitaxel (PTX)-induced growth suppression was enhanced by 4D3. Furthermore, 4D3 increased both intracellular PTX concentration (in both cells) and apoptosis. In the mouse model, 4D3 promoted the antitumor effect of PTX on subcutaneous tumors and reduced lung metastasis. The combination of PTX and 4D3 reduced M2 macrophages and mesenchymal stem cells in the tumor. 4D3 also reduced stemness of the tumors in association with increase in the intratumoral pH. Moreover, concurrent treatment of 4D3, PTX, or tamoxifen; or with PTX and tamoxifen in MDA-468 also showed the same level of antitumor activity and survival as MCF-7. Furthermore, in bone metastasis model, combination of PTX and bisphosphonate with 4D3 promoted tumor growth in both cells.

Conclusions

CLDN4 targeting of the antibody facilitated existing therapeutic effects.

Figures

Background

Methods

Results

Discussion

Conclusion

Abbreviations

Declarations

References

Tables

Learn more about our company.